Sagimet BiosciencesSTU:0O2 +1.66%10 Quick Ratio is 20.33 as of Mar. 2026, which is 0% below its 10-year median of 20.35. GuruFocus rates STU:0O2 with a GF Score™ of 10/100. The stock has 2 warning signs investors should review. Among 1,413 Biotechnology companies, Sagimet Biosciences ranks better than 92.57% on this metric.
Sagimet Biosciences has a quick ratio of 20.33. It generally indicates good short-term financial strength.
The historical rank and industry rank for Sagimet Biosciences's Quick Ratio or its related term are showing as below:
STU:0O2'
s Quick Ratio Range Over the Past 10 Years
Min: 4.04 Med: 20.35 Max: 43.12
Current: 20.34
During the past 7 years, Sagimet Biosciences's highest Quick Ratio was 43.12. The lowest was 4.04. And the median was 20.35.
STU:0O2's Quick Ratio is ranked better than 92.57% of 1413
companies
in the Biotechnology industry
Industry Median: 3.6
vs STU:0O2: 20.34
Sagimet Biosciences (STU:0O2) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Sagimet Biosciences Quick Ratio Related Terms
Sagimet Biosciences Quick Ratio Historical Data
* Premium members only.
The historical data trend for Sagimet Biosciences's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:0O2 vs NGNE, UPB, STTK: Quick Ratio Comparison
For the Biotechnology subindustry, Sagimet Biosciences's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sagimet Biosciences Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sagimet Biosciences's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Sagimet Biosciences's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Sagimet Biosciences's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sagimet Biosciences (STU:0O2) has a Quick Ratio of 20.33 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sagimet Biosciences and its competitors. This is near median its historical median of 20.35. Over the past decade, Sagimet Biosciences' Quick Ratio has ranged from 4.04 to 43.12. According to the industry distribution chart, Sagimet Biosciences ranks #105 out of 1413 companies in the Biotechnology industry, placing it in the top 7.4%.
Is Sagimet Biosciences' Quick Ratio too high?
Sagimet Biosciences' current Quick Ratio of 20.33 is near median its 10-year median of 20.35. Over the past 10 years, this metric has ranged from a low of 4.04 to a high of 43.12. The Biotechnology industry median Quick Ratio is 3.60. Sagimet Biosciences' value of 20.33 is 464.7% above this industry median. Based on the distribution chart, Sagimet Biosciences ranks #105 out of 1413 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sagimet Biosciences has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Sagimet Biosciences' Quick Ratio compare to NGNE and UPB?
According to the Biotechnology industry distribution chart, Sagimet Biosciences ranks #105 out of 1413 companies for Quick Ratio. This places Sagimet Biosciences in the top 7% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Sagimet Biosciences' value of 20.33 is 464.7% above this benchmark. Historically, Sagimet Biosciences' own Quick Ratio has ranged from 4.04 to 43.12 over the past decade. While the company's 10-year median is 20.35 vs. the industry median of 3.60, Sagimet Biosciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,413 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sagimet Biosciences's current Quick Ratio of 20.33 is 464.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Sagimet Biosciences and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sagimet Biosciences's current Quick Ratio is 20.33, which is near median its own 10-year median of 20.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sagimet Biosciences stock overvalued right now?
Sagimet Biosciences (STU:0O2) has a current Quick Ratio of 20.33. The current Quick Ratio is 20.33, which is near median its 10-year median of 20.35 and 464.7% above the Biotechnology industry median of 3.60. Sagimet Biosciences' overall GF Score™ is 10/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Sagimet Biosciences (STU:0O2), the current Quick Ratio is 20.33 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Sagimet Biosciences Inc a clinical-stage biopharmaceutical company developing novel therapeutics called fatty acid synthase (FASN) inhibitors that target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. Its drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), acne and select forms of cancer. Its second FASN inhibitor, TVB-3567, is a potent and selective small molecule FASN inhibitor in development for acne. It operates as a single business segment, developing and commercializing therapeutics for the treatment of MASH and other diseases where FASN plays a pathogenic role.
10GF Score
Get the complete analysis for STU:0O2
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:0O2 has been successfully added to your 
